Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Pokerface schreef op 15 maart 2017 11:52 :
PB ziet er hoopvol uit. Er staat veel te gebeuren de komende tijd.
Klopt. Dit is werkelijk een topbedrijf . Ontwikkelingen volgen elkaar vliegensvlug op . En het mooiste is, dat nog niet veel beleggers dit in de gaten hebben .
nog 3-4 persberichten tegoed in de komende 2 weken . Zie persbericht .
Inderdaad, maar niemand lijkt het te willen zien. Of men weet al wat er in staat. Het kan natuurlijk alle kanten op bij biotech. Je kan natuurlijk altijd na de PB's instappen.
Die PB's gaan alleen over het starten van nieuwe studies... Gaat de koers niet omhoog lijkt me. Pas bij bericht van resultaten over die studies en dat duurt nog even.
Benny Lava schreef op 18 maart 2017 10:25 :
Die PB's gaan alleen over het starten van nieuwe studies... Gaat de koers niet omhoog lijkt me. Pas bij bericht van resultaten over die studies en dat duurt nog even.
Ik denk van wel . Pipeline wordt steeds groter en komt steeds verder . Steeds meer partners . Als GLPG een nieuwe studie in fase 2 start , vliegt de koers wel omhoog . Waarom zou dat hier niet zo zijn . Dit aandeel wordt(nog) zwaar onderschat . Kwaliteit zal vanzelf boven komen boven drijven en dan ontstaat er een run . Ik ben mijn positie nog steeds verder aan het uitbreiden .
Ik denk ook dat de koers wel op die PB's gaat reageren. Gepartnerde medicijnen willen nog wel eens mijlpaal betalingen opleveren bij start of finish van een onderzoek en de start van een onderzoek geeft meestal ook beter zicht op de einddatum van een onderzoek. De koers kan in de aanloop naar zo'n einddatum oplopen omdat aandeelhouders bepaalde verwachtingen hebben bij een onderzoek. Een kleine kanttekening: Tegenvallende resultaten geven natuurlijk ook een reactie op de koers...
Hoppa En de volgende partnership in the pocket Published: 07:00 CET 21-03-2017 /GlobeNewswire /Source: argenx N.V. / : ARGX /ISIN: NL0010832176 argenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseases - Differentiated antibody to address complement target - - Represents latest collaboration to stem from the argenx Innovative Access Program - - argenx granted option to license program after preclinical proof-of-concept - 21 March 2017 Breda, the Netherlands/Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it has entered into a new collaboration with Broteio Pharma B.V. to develop an antibody against a novel target in the complement cascade with therapeutic potential in autoantibody- and complement-mediated indications including autoimmune haemolytic anaemia (AIHA) and antibody mediated rejection (AMR) following organ transplantation. "This collaboration represents the latest success for our Innovative Access Program and aligns with our corporate mission to develop differentiated antibodies for cancer and severe autoimmune diseases. The novel antibody targets a component of the complement cascade with therapeutic potential in both orphan and large market indications like Ischemia/Reperfusion Injuries (IRI)," comments Tim Van Hauwermeiren, CEO of argenx. "This new therapeutic antibody has the potential to act alongside our lead product candidate ARGX-113 in a synergistic fashion. ARGX-113 targets FcRn in order to clear pathogenic IgG antibodies while our new complement-targeted antibody can also address IgM mediated autoimmune diseases. This transaction positions us to further build out the depth and breadth of our autoimmune disease pipeline." Under the terms of the agreement, argenx and Broteio will jointly develop the complement-targeted antibody to establish preclinical proof-of-concept using argenx's proprietary suite of technologies. Upon successful completion of these studies, argenx may exercise an exclusive option to license the program and assume responsibility for further development and commercialization. About the Innovative Access Program Through our Innovative Access Program (IAP) argenx is able to serially collaborate closely with academic experts and small biotech companies, bringing antibody discovery technologies to the heart of novel target research. The IAP allows our partners use of our technologies for the development of antibodies to help validate novel targets. In return argenx is granted early access to these targets. The diversity of argenx's SIMPLE AntibodyTM immune repertoires help streamline target validation, with the potential to transform novel proteins into next generation therapeutic antibody programs. Role of complement in auto-immune diseases The classical pathway of the complement system is composed of a series of proteins that are activated when IgG or IgM (auto)antibodies bind to their targets. This mechanism contributes to tissue damage and organ dysfunction in a number of (auto)immune inflammatory diseases. The novel complement target is key in the lysis of antibody-decorated cells and is active when an immune reaction is taking place. The novel antibody has therapeutic potential in orphan and large population autoimmune indications including autoimmune haemolytic anaemia (AIHA) and antibody mediated rejection (AMR). About Broteio Based in Utrecht, the Netherlands, Broteio Pharma B.V. ("Broteio") is a joint venture between Prothix B.V. and Bioceros Holding B.V. established to develop anti-complement monoclonal antibodies. About argenx argenx a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates. www.argenx.com
En de koers doet weer helemaal niks. Kan de waarde van dit PB ook niet echt inschatten.
Dit alles is uiteraard waarde op LT . Voor nu geldt dat de risico's steeds verder gespreid worden over meer partnerships en pipeline . Argen-X schiet altijd onverwacht naar boven . Ik verwacht wel in de komende periode een aantal hogere koersdoelen . Geduld . Zie hoe het GLPG is vergaan . ALs er 1 schaap over de dam is ......
Achter deze clubs zit Prof erik Hack, topper in dit gebied en destijds bij Crucell. Anti complement antibodies zijn nog nooit echt ontwikkeld omdat de complement eiwitten nooit als goede tragtes werden beschouwd. Deal is inderdaad nog moeilijk op waarde te schatten dus doet de koers niet veel. Ben ondanks het cashen van Tim weer klein beetje ingestapt want blijf de technologie en slimme mensen als de CSO Hans de Haard aantrekkelijk vinden.
Welcome terug Fly Jij was de trendsetter om dit aandeel onder de aandacht te brengen ( en terecht zo blijkt). Je weet dat ik in het begin een beetje afhoudend/afwachtend was . Heb echter na veel lezen mijn positie opgebouwd vanaf ca 10 euro . Deze gaat er bij mij niet meer uit de komende jaren . Het bedrijf ontwikkeld zich gedegen en razend snel . Paar mooie potentiële blockbusters in de pipeline en steeds meer partnerships . LT Het is jammer dat mijn aandelen aantallen niet omgedraaid zijn tov Ablynx . Daar heb ik er nl 2 x zoveel van . Daar gaat het echter met enige vertraging ook binnenkort los. vandaag KBC biotech & Healthcare Conference, Brussels March 29, 2017 Tim Van Hauwermeiren, CEO & Joke Comijn, IR Manager
Dank Bio en was eerder uitgestapt met mooie winst door verkopen van Tim. begreep echter dat Hans de CSO en de andere MT leden nog niet verzilverd hebben dus zal Tim zoasl wel meer CEO's wat aan het spelen en bij aan cashen zijn. Ben weer beetje ingestapt omdat platform nog steeds geweldig is en er van veel kanten interesse bestaat.
De persberichten zouden nu toch wel zo'n beetje moeten gaan binnen druppelen de komende dagen . The past year was one of significant growth for argenx, and we have seen the momentum maintained into the first months of 2017. We continued to build our proprietary pipeline and advanced both our lead programs, ARGX-113 and ARGX-110, through key safety and early efficacy inflection points. Our early studies guided us on the attributes of each drug and enabled us to choose the indications we believe were best-suited for Phase 2 study. By the end of the first quarter, we plan to launch four proof-of-concept Phase 2 studies: MG and ITP for ARGX-113, and AML and TCL for ARGX-110,” commented Tim Van Hauwermeiren, CEO of argenx. “We were also busy outside the clinic with the start of our collaboration with AbbVie for our novel immuno-oncology product, ARGX-115,
argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia March 31, 2017 •Topline data from the study expected in second half of 2018 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the dosing of the first patient in a Phase II proof-of-concept study of ARGX-113 in patients with primary immune thrombocytopenia (ITP). “The initiation of the second Phase II trial for our lead candidate, ARGX-113, is an important milestone for the company as it exemplifies the breadth of potential this compound has to address a wide variety of diseases that are driven by pathogenic IgGs,” commented Nicolas Leupin, CMO of argenx. “We believe ARGX-113 could be a breakthrough therapy in an indication like ITP where current therapies do not adequately address symptoms or achieve remissions.” The double-blind, placebo controlled Phase II study will enrol up to 36 ITP patients with platelet levels lower than 30 million per milliliter. ARGX-113 will be dosed on top of current standard of care, corticosteroids and/or immunomodulatory agents and/or TPO-R agonists. The primary endpoints of the trial are safety and tolerability and secondary endpoints include effect on platelet count and use of rescue treatment, and an assessment of pharmacokinetics (PK) and pharmacodynamic (PD) markers. In Phase I clinical trial, ARGX-113 demonstrated favorable safety and tolerability across multiple doses and dosing regimens with promising pharmacodynamics effects relating to speed, depth and duration of IgG reduction. About ARGX-113 We are developing our lead product candidate, ARGX-113, for the treatment of patients with myasthenia gravis and primary immune thrombocytopenia, both of which are rare and severe autoimmune diseases associated with high levels of pathogenic IgGs. Few innovative biologic treatments have been approved addressing these circulating auto-antibodies and severe unmet medical need exists. ARGX-113 is the Fc-portion of an antibody and utilizes our ABDEG engineering technology. It is designed to block the recycling of IgG antibodies, which results in their removal from circulation. The development work on ARGX-113 is done in close collaboration with Prof. E. Sally Ward (University of Texas Southwestern Medical and Texas A&M University Health Science Center, a part of Texas A&M University (“TAMHSC”)). About argenx argenx a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates. www.argenx.com
Bedankt Breugell voor het plaatsten . Had ik het goed verwacht . Mooie ontwikkelingen
Belangrijke stap en hopen dat ARGX-113 werkzaam is!
PB:argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients Interim data expected by end of 2017 12 April 2017 Breda, the Netherlands/Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the initiation of a Phase II trial of ARGX-110 as a monotherapy in patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL). ARGX-110 is the Company's SIMPLE Antibody(TM) targeting CD70. "We have previously observed evidence of biological activity and a promising safety profile in several CD70-positive CTCL patients treated in an ongoing Phase I safety-expansion cohort, resulting in several patients with partial response or stable disease. Based on these preliminary results, we opted to further evaluate ARGX-110 as a monotherapy in an exploratory Phase II study to demonstrate the intrinsic activity of the drug in relapsed/refractory CTCL patients and to broaden our efficacy database," commented Nicolas Leupin, CMO of argenx. "This marks the second Phase 1/2 study of ARGX-110 with the first having launched in December 2016 as a combination therapy with standard of care in AML." The Phase II clinical trial will enroll up to 10 additional relapsed/refractory CTCL patients, and will be conducted at multiple centers in Europe. The primary endpoints of the trial are safety and efficacy and secondary endpoints include pharmacokinetics and immunogenicity. Interim data are expected by the end of 2017, and we expect to report topline data in the second half of 2018. ARGX-110 is also being studied as a combination therapy with standard of care azacitidine in newly diagnosed, elderly acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) patients. About ARGX-110 ARGX-110 is a SIMPLE Antibody(TM) targeting CD70, an immune checkpoint target involved in hematological malignancies, several solid tumors and severe autoimmune diseases. ARGX-110 works in three ways: i) blocks growth of tumor cells, ii) kills cancer cells and iii) restores immune surveillance against tumors (Silence K. et al. mAbs 2014; 6 (2):523-532). ARGX-110 is currently being evaluated in a Phase II combination trial in patients with newly diagnosed acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome and a Phase II trial in patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL). Preclinical work on ARGX-110 in AML was done in collaboration with the Tumor Immunology Lab of Prof. A. F. Ochsenbein at the University of Bern, who won together with Prof Manz from the University Hospital of Zürich, the prestigious 2016 Otto Naegeli Prize for his breakthrough research on CD70/CD27 signaling with therapeutic potential for cancer patients. About CTCL Lymphoma is the most common type of blood cancer. TCL accounts for 6% of all cases of lymphoma and can be divided into subtypes such as peripheral TCL (PTCL), angioimmunoblastic TCL (AITL), anaplastic large cell lymphoma (ALCL), and CTCL. According to the Cutaneous Lymphoma Foundation, the incidence of CTCL in the United States is approximately 3,000 new cases per year. The two most common types of CTCL are mycosis fungoides, representing approximately 50% of CTCL patients, and a more advanced form known as Sezary syndrome, representing approximately 15% of CTCL patients. In both mycosis fungoides and Sezary syndrome, visible skin lesions offer an ongoing means with which to monitor both the progression of disease and the impact of treatment. Sezary syndrome is distinguished by the presence of malignant lymphocytes in the blood, an extensive rash covering over 80% of the body and tumors visible on the skin. About argenx argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTMPlatform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates. www.argenx.com
Wederom erg mooi persbericht .
PB:argenx receives first preclinical milestone payment in AbbVie collaboration 13 April 2017 Breda, the Netherlands/Ghent, Belgium argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the achievement of the first of two preclinical milestones on its way to the investigational new drug (IND) filing of ARGX-115, triggering a $ 10 million payment from AbbVie. In April 2016, argenx entered into a collaboration agreement with AbbVie to develop and commercialize ARGX-115. Under the terms of the collaboration agreement, argenx is responsible for conducting and funding all ARGX-115 research and development activities up to completion of IND-enabling studies. argenx has granted AbbVie an exclusive option, for a period following completion of IND-enabling studies, to obtain a worldwide, exclusive license to the ARGX-115 program to develop and commercialize products. argenx is eligible to receive two near-term preclinical milestones of $ 10 million each. The first milestone was achieved today. About ARGX-115 ARGX-115 employs argenx's SIMPLE Antibody(TM) technology and works by stimulating a patient's immune system after a tumor has suppressed the immune system by co-opting immunosuppressive cells such as activated regulatory T-cells (Tregs). While the normal function of Tregs is to suppress portions of the immune system to prevent a self-directed immune response through the release of active transforming growth factor beta (TGF-beta), Tregs can also prevent the immune system from recognizing and suppressing pathogenic cells including cancer cells. By binding to glycoprotein A repetitions predominant (GARP), which plays a key role in the regulation of production and release of active TGF-beta, ARGX-115 works to limit the immunosuppressive activity of Tregs and thereby stimulate the immune system to attack cancer cells. We believe this specific inhibition of TGF-beta release by Tregs is potentially superior as a therapy to systemic inhibition of TGF-beta activity or the depletion of Tregs with a potentially improved safety profile. ARGX-115 was discovered under argenx's Innovative Access Program with the de Duve Institute / Université Catholique de Louvain / WELBIO. About argenx argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody(TM) Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates. www.argenx.com
Is toch weer mooi 10 M cash in
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee